STOCK TITAN

GENFIT S.A. American Depositary Shares - $GNFT STOCK NEWS

Welcome to our dedicated page for GENFIT S.A. American Depositary Shares news (Ticker: $GNFT), a resource for investors and traders seeking the latest updates and insights on GENFIT S.A. American Depositary Shares stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GENFIT S.A. American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GENFIT S.A. American Depositary Shares's position in the market.

-
GENFIT S.A. American Depositary Shares

Nasdaq:GNFT

GNFT Rankings

GNFT Stock Data

181.00M
43.75M
1.3%
0.19%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
Loos

About GNFT

genfit is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as nash - nonalcoholic steatohepatitis) or the bowel (such as the inflammatory bowel disease). genfit is committed to contribute to bringing new medicines to market for patients who lack suitable solutions, and strives to implement mutually beneficial approaches that combine novel drugs and biomarkers. its research programs have resulted in the creation of a rich and diversified pipeline of drug candidates, including genfit’s lead proprietary compound, gft505, that is completing a phase 2b study in nash.